Fulgent Genetics (FLGT)
(Delayed Data from NSDQ)
$21.75 USD
-0.04 (-0.18%)
Updated May 10, 2024 04:00 PM ET
After-Market: $21.75 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
FLGT 21.75 -0.04(-0.18%)
Will FLGT be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for FLGT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FLGT
Fulgent Genetics, Inc. (FLGT) Reports Q1 Loss, Misses Revenue Estimates
American Well Corporation (AMWL) Reports Q1 Loss, Misses Revenue Estimates
FLGT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Privia Health (PRVA) Misses Q4 Earnings Estimates
Health Catalyst (HCAT) Q4 Earnings and Revenues Beat Estimates
Fulgent Genetics, Inc. (FLGT) Reports Q3 Loss, Tops Revenue Estimates
Other News for FLGT
What's Driving Twist Bioscience Corp's Surprising 13% Stock Rally?
Analysts Have Conflicting Sentiments on These Healthcare Companies: Fulgent Genetics (FLGT), Cigna (CI) and PROCEPT BioRobotics (PRCT)
Fulgent Genetics Inc (FLGT) Q1 2024 Earnings Call Transcript Highlights: Navigating Challenges ...
FLGT Stock Earnings: Fulgent Genetics Beats EPS, Misses Revenue for Q1 2024
Fulgent Genetics, Inc. (FLGT) Q1 2024 Earnings Call Transcript